Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Show other versions (1)

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, McShane, H
Format:	Journal article
Sprog:	English
Udgivet:	2011

Lignende værker

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
af: Ota, M, et al.
Udgivet: (2011)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
af: Odutola, A, et al.
Udgivet: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
af: Odutola, A, et al.
Udgivet: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
af: Brookes, R, et al.
Udgivet: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
af: Roger H Brookes, et al.
Udgivet: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
af: Roger H. Brookes, et al.
Udgivet: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
af: Rowland, R, et al.
Udgivet: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
af: Pathan, A, et al.
Udgivet: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
af: Pathan, A, et al.
Udgivet: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
af: Meyer, J, et al.
Udgivet: (2013)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
af: Whelan, K, et al.
Udgivet: (2009)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
af: Owiafe, P, et al.
Udgivet: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
af: Ibanga, H, et al.
Udgivet: (2006)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
af: Meyer, J, et al.
Udgivet: (2013)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
af: Imoukhuede, E, et al.
Udgivet: (2006)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
af: White, A, et al.
Udgivet: (2013)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
af: Harris, S, et al.
Udgivet: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
af: Sander, C, et al.
Udgivet: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
af: Kathryn T. Whelan, et al.
Udgivet: (2011-01-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
af: Mensah, V, et al.
Udgivet: (2017)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
af: Mcshane, H
Udgivet: (2008)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
af: Dieye, T, et al.
Udgivet: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
af: Hawkridge, T, et al.
Udgivet: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
af: Satti, I, et al.
Udgivet: (2014)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Udgivet: (2011-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
af: Rowland, R, et al.
Udgivet: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
af: Mcshane, H, et al.
Udgivet: (2016)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
af: Minassian, A, et al.
Udgivet: (2011)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
af: Scriba, T, et al.
Udgivet: (2011)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
af: Wajja, A, et al.
Udgivet: (2017)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
af: Anne Wajja, et al.
Udgivet: (2017-05-01)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
af: Tandakha N Dieye, et al.
Udgivet: (2013-01-01)

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
af: Mullarkey, C, et al.
Udgivet: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
af: Thomas, Z, et al.
Udgivet: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
af: Tandakha N. Dieye, et al.
Udgivet: (2013-01-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
af: Satti, I, et al.
Udgivet: (2014)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
af: Mcshane, H, et al.
Udgivet: (2005)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
af: Minhinnick, A, et al.
Udgivet: (2016)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
af: Tameris, M, et al.
Udgivet: (2014)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
af: Griffiths, K, et al.
Udgivet: (2011)